Goldman Sachs
NBSE

Goldman Sachs’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Goldman Sachs’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-4
Closed -$1K – 6915
2017
Q2 		$1K Buy
+4
New +$1.07K ﹤0.01% 6746
2015
Q1 		– Sell
-40
Closed -$132K – 7336
2014
Q4 		$132K Hold
40
– – ﹤0.01% 6437
2014
Q3 		$115K Sell
40
-665
-94% -$2.2M ﹤0.01% 6516
2014
Q2 		$2.68M Buy
+705
New +$2.65M ﹤0.01% 3686

Other funds holding NBSE

GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CMU
Carnegie Mellon University Pittsburgh, Pennsylvania $64.3M AUM 35.71% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
JAMONY
Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

Goldman Sachs's NBSE Position: Q4 2022 in Review

Goldman Sachs sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q4 2022, closing a stake of 4,110 shares — an estimated $32K sold.

Goldman Sachs first reported a position in NBSE in Q3 2013 and held it in 19 quarters. The position peaked at $2.04M in Q2 2014. 34 funds tracked by Wall St. Rank hold NBSE as of Q4 2022.

  • Goldman Sachs reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Goldman Sachs sold 4,110 NeuBase Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $32K.
  • Goldman Sachs first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q3 2013 and held it in 19 quarters.
  • Goldman Sachs's NeuBase Therapeutics, Inc. Common Stock position peaked at $2.04M in Q2 2014.
  • 34 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Goldman Sachs's 13F filing for Q4 2022, filed 13 Feb 2023.